EP Patent

EP4101447A1 — Nant cancer vaccine

Assigned to Nant Holdings IP LLC · Expires 2022-12-14 · 3y expired

What this patent protects

Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.

USPTO Abstract

Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.

Drugs covered by this patent

Patent Metadata

Patent number
EP4101447A1
Jurisdiction
EP
Classification
—
Expires
2022-12-14
Drug substance claim
No
Drug product claim
No
Assignee
Nant Holdings IP LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.